CardioSignal Raises $10 Million in Series A as the First Technology to Detect Major Heart Diseases without Specialized Medical Hardware
Summary
CardioSignal Raises $10 Million in Series A as the First Technology to Detect Major Heart Diseases without Specialized Medical HardwarePatented Advances in Gyrocardiography Bring Affordable, Clinical-Grade Disease Detection to Remote Patients with SmartphonesCardioSignaltoday announced the closing of $10 million in Series A funding, led by DigiTx Partners, with participation from Sandwater and existing investor Maki.vc. We can support the shift in cardiovascular care from treating complications to earlier detection and prevention, said cardiologist Dr. Juuso Blomster,founder and CEO of CardioSignal.CardioSignal has the potential to meaningfully impact heart disease on a global basis. Besides the ability to detect various heart diseases, which continue to be one of the common causes of death, CardioSignal has lowered the barrier to the adoption of its technology by making it readily available to all individuals who have smartphones. We can reach millions of at-risk patients and make a real impact, said David J. Kim, managing director of DigiTx Partners. The MODE-AF Study February 2019 CardioSignal application earns CE Marking as a Class IIa medical device in Europe for detecting signs of atrial fibrillation October 2022 CardioSignal wins the American Heart Association (AHA) EMpowered to Serve grant to advance health equity November 2022 Ursula Burns, former chairwoman and CEO of Xerox Corporation, member of Mayo Clinics Board of Trustees, and Uber board member, joins CardioSignals Board of Directors August 2023 The technologys heart failure detection capabilities presented at the European Society of Cardiology Annual Meeting in AmsterdamCardioSignal is a brand and a product by Precordior Ltd, an ISO 13485 and 27001 certified health technology company formed in 2017 and headquartered in Turku, Finland.